» Articles » PMID: 35336889

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons

Abstract

In 2016, the WHO announced a plan to eliminate viral hepatitis as a public health threat by 2030. In this narrative review, experts from Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia assessed the feasibility of achieving the WHO 2030 target for HCV infections in Central Europe. They focused mainly on HCV micro-elimination in prisons, where the highest incidence of HCV infections is usually observed, and the impact of the COVID-19 pandemic on the detection and treatment of HCV infections. According to the presented estimates, almost 400,000 people remain infected with HCV in the analyzed countries. Interferon-free therapies are available ad libitum, but the number of patients treated annually in the last two years has halved compared to 2017-2019, mainly due to the COVID-19 pandemic. None of the countries analyzed had implemented a national HCV screening program or a prison screening program. The main reason is a lack of will at governmental and prison levels. None of the countries analyzed see any chance of meeting the WHO targets for removing viral hepatitis from the public threat list by 2030, unless barriers such as a lack of political will and a lack of screening programs are removed quickly.

Citing Articles

Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.

Petkeviciene J, Voeller A, ciupkeviciene E, Razavi-Shearer D, Liakina V, Jancoriene L BMC Public Health. 2024; 24(1):1055.

PMID: 38622549 PMC: 11020450. DOI: 10.1186/s12889-024-18470-5.


Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.

Piselli P, Boschini A, Gianfreda R, Nappo A, Cimaglia C, Scarfo G Viruses. 2024; 16(3).

PMID: 38543741 PMC: 10974793. DOI: 10.3390/v16030375.


Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland.

Genowska A, Zarebska-Michaluk D, Strukcinskiene B, Razbadauskas A, Moniuszko-Malinowska A, Jurgaitis J J Clin Med. 2023; 12(12).

PMID: 37373617 PMC: 10299469. DOI: 10.3390/jcm12123922.


Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic.

Frankova S, Uzlova N, Merta D, Pitova V, Sperl J Life (Basel). 2023; 13(4).

PMID: 37109461 PMC: 10144836. DOI: 10.3390/life13040932.


Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.

Brzdek M, Zarebska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R World J Gastroenterol. 2023; 29(6):949-966.

PMID: 36844142 PMC: 9950869. DOI: 10.3748/wjg.v29.i6.949.


References
1.
Moazen B, Dolan K, Moghaddam S, Lotfizadeh M, Duke K, Neuhann F . Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union. Epidemiol Rev. 2020; 42(1):19-26. DOI: 10.1093/epirev/mxaa003. View

2.
Piekarska A, Tomasiewicz K, Halota W, Jaroszewicz J, Krygier R, Malkowski P . Searching for the optimal population for hepatitis C virus screening in Poland. Clin Exp Hepatol. 2020; 6(2):74-76. PMC: 7380468. DOI: 10.5114/ceh.2020.94969. View

3.
Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J . Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J. 2021; 18(1):69. PMC: 8247095. DOI: 10.1186/s12954-021-00519-y. View

4.
Gamkrelidze I, Pawlotsky J, Lazarus J, Feld J, Zeuzem S, Bao Y . Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021; 41(3):456-463. DOI: 10.1111/liv.14779. View

5.
Papic N, Radmanic L, Dusek D, Kurelac I, Zidovec Lepej S, Vince A . Trends of Late Presentation to Care in Patients with Chronic Hepatitis C during a 10-Year Period in Croatia. Infect Dis Rep. 2020; 12(3):74-81. PMC: 7768519. DOI: 10.3390/idr12030016. View